Overexpression of the multidrug effl ux transport P-glycoprotein may play an important role in pharmacoresistance. 
methods
Two (test-retest) dynamic [ 11 C]laniquidar PET scans were performed in 8 healthy subjects. Plasma input functions were obtained using on-line arterial blood sampling with metabolite corrections derived from manual samples. Co-registered T1 MRI scans were used for region-of-interest defi nition. Time-activity curves were analysed using various plasma input compartmental models.
results [ 11 C]Laniquidar was metabolised rapidly with a parent plasma fraction of 50% at 10 minutes post tracer injection. In addition, the fi rst pass extraction of [ 11 C]laniquidar was low. Using conventional models, [ 11 C]laniquidar time-activity curves were best fi tted to an irreversible single-tissue compartment (1T1K) model. Nevertheless, signifi cantly better fi ts were obtained using 2 parallel single-tissue compartments, one for parent tracer and the other for labeled metabolites (dual-input model). Robust K 1 results were also obtained by fi tting the fi rst 5 minutes of PET data to the 1T1K model, at least when 60 minutes plasma input data were used. For both models, test-retest variability of [ 11 C]laniquidar K 1 was approximately 19%.
Conclusion
Accurate quantifi cation of [ 11 C]laniquidar kinetics in the brain is hampered by its fast metabolism and the likelihood that labeled metabolites enter the brain. Best fi ts for the entire 60 minutes of data were obtained using a dual-input model, accounting for uptake of [ 11 C]laniquidar and its labeled metabolites. Alternatively, K 1 could be obtained from a 5-minutes scan using a standard 1T1K model. In both cases, test-retest variability of K 1 was approximately 19%.
InTroduCTIon
In many central nervous system disorders, patients respond poorly to drug treatment. For example, 30% of all patients with epilepsy are therapy resistant. 1 In epilepsy, pharmacoresistance is attributed, at least in part, to upregulation of multidrug effl ux transporters at the blood-brain barrier, including P-glycoprotein. 2 These effl ux transporters transport substrates (including many central nervous system drugs) back into the circulation, thereby restricting their build-up in the brain. 2 Consequently, cerebral drug levels may be too low for a therapeutic eff ect. Positron emission tomography (PET) is a non-invasive molecular imaging technique that has the potential to measure distribution and function of P-glycoprotein in the human brain. Several P-glycoprotein tracers have been proposed, but in practice only (R)-[
11 C]verapamil and [ 11 C]N-desmethyl-loperamide have been used to assess P-glycoprotein function . [3] [4] [5] [6] [7] As both ligands are substrates of P-glycoprotein, their concentration in the brain is low. In case of overexpression of P-glycoprotein, cerebral concentrations will be reduced even further. Consequently, noise levels will increase and accurate measurements of P-glycoprotein overexpression will become diffi cult. At present, the only option to assess P-glycoprotein overexpression is to perform 2 scans in the same subject, one before and the other after P-glycoprotein inhibition 5 , but the statistical limitations mentioned above remain. Measurement of P-glycoprotein expression should be easier using a P-glycoprotein inhibitor rather than a P-glycoprotein substrate tracer, because such an antagonist should bind in a dose-dependent manner to P-glycoprotein, that is overexpression of P-glycoprotein should result in an increased signal. Third generation P-glycoprotein inhibitors, such as laniquidar, elacridar and tariquidar have recently been labeled with carbon-11. [8] [9] [10] Unfortunately, initial studies on uptake of [ 11 C]laniquidar in rat brain have been inconclusive 10 , and to date only a biodistribution study has been performed in humans. 11 The purpose of the present study was to develop a tracer kinetic model for quantifi cation of [ 11 C]laniquidar kinetics in the brain of healthy volunteers and to defi ne test-retest variability of the most appropriate outcome measure.
mATerIAls And meThods subjects
Healthy subject recruitment, screening, and inclusion and exclusion criteria were identical to those described previously. 12 The study was approved by the Medical Ethics Review
Committee of the VU University Medical Center and, prior to inclusion, all subjects gave written informed consent following a complete written and verbal description of the study.
magnetic resonance imaging (mrI)
All subjects underwent a structural MRI scan using a 3Tesla MRI scanner (Signa HDXt, GE Healthcare) according to a standard protocol including T1 weighted 3-D magnetizationprepared rapid acquisition gradient-echo images covering the whole brain, axial fluid attenuated inversion recovery images and T2 axial images. Coronal magnetizationprepared rapid acquisition gradient-echo images were used for co-registration and for region-of-interest (ROI) definition. 
PeT data acquisition
In principle, participants underwent 2 identical PET scans on the same day. If this was not possible the maximum interval between both scans was 1 month. PET scans were obtained under standard resting conditions using an ECAT EXACT HR+ scanner (Siemens/CTI). 13 All subjects received both indwelling arterial (radial artery) and venous cannulas that were used for arterial blood sampling and tracer injection, respectively. After cannulation, patients were transferred to the scanner room and positioned such that the head was in the centre of both axial and transaxial fields of view of the scanner. The head was immobilized to reduce movement artefacts and, using laser beams, positioned and checked for movement during scanning. First, a 10-minutes transmission scan was performed in 2-dimensional acquisition mode using 3 retractable rotating line sources. This scan was used to correct the subsequent emission scan for photon attenuation. After this transmission scan, an intravenous injection of approximately 370 MBq [ 11 C]laniquidar was administered, simultaneously starting a dynamic emission scan in 3-dimensional acquisition mode. Using an infusion pump (Med-Rad), [ 11 C]laniquidar (in a 2.5 mL vial) was injected at a rate of 0.8 mL·s -1 , which was followed by a flush of 42 mL saline at a rate of 2.0 mL·s -1 . The emission scan consisted of 24 frames with increasing frame duration (1 x 15, 3 x 5, 3 x 10, 2 x 30, 3 x60, 2 x 150 and 10 x 300 s) and a total scan duration of 60 minutes. During the emission scan, arterial blood was withdrawn continuously at a rate of 5 mL·min -1 for the first 5 minutes and 2.5 mL·min -1 thereafter using an automatic on-line blood sampler (Veenstra Instruments). 14 Continuous withdrawal was interrupted briefly at 2.5, 5, 10, 20, 30, 40 and 60 minutes after tracer injection for manual collection of 10-mL blood samples. After each manual sample, the arterial line was flushed with a heparinized saline solution. Following a resting period of at least 3 hours to allow for decay of carbon-11, the scanning sequence was repeated in exactly the same manner. Plasma and whole-blood activity concentrations of the manual samples were measured using a Wallac Wizard 1480 gammacounter, which was cross-calibrated against the PET scanner. Manual blood samples were also used to determine plasma fractions of [
11 C]laniquidar and its radiolabeled metabolites. Metabolite analysis was performed using solid-phase extraction. In brief, 1 mL of plasma was diluted with 2 mL of acidified water (10 µL 6M HCl) and passed over an activated SepPak tC18 (Waters). After washing with 3 mL of water, the column was eluted with 3 mL of methanol. The first two fractions consisted of polar metabolites. Further analysis of the non-polar methanol fraction showed only 1 compound (i.e. [ 11 C]laniquidar).
PeT data analysis
PET sinograms were corrected for dead time, scatter, randoms, decay and tissue attenuation. Images were reconstructed using a standard filtered back projection algorithm and an image matrix size of 256 x 256 x 63, resulting in a voxel size of 1.2 x 1.2 x 2.4 mm and a spatial resolution of approximately 7 mm in the center of the field of view. Next, PET and MRI images were spatially co-registered using a mutual information registration algorithm incorporated within Vinci software (Max Planck Institute). 15 Structural T1 MRI images were segmented in probability maps of gray matter, white matter and cerebrospinal fluid using statistical parametric mapping (SPM5; Wellcome Trust Centre for Neuroimaging). 16 Thirty-eight ROIs were defined on the segmented MRI using a probabilistic template as implemented within PVElab software. 17 Gray matter voxels that were not included in any of these spatially localized ROIs were assigned to a rest-of-gray-matter ROI, so that an additional analysis for total gray matter could be performed. All ROIs were mapped onto the co-registered dynamic PET images, thus generating corresponding time-activity curves.
The following ROIs were used for further analysis: frontal (volume-weighted average of orbital frontal, medial inferior frontal and superior frontal), parietal, temporal (volumeweighted average of superior temporal and medial inferior temporal), medial temporal lobe (volume-weighted average of hippocampus and entorhinal), posterior cingulate and anterior cingulate, occipital, and cerebellum. Finally, a global brain ROI was defined as the volume-weighted average of all 38 original gray matter ROIs.
Kinetic analysis
Whole-blood radioactivity concentrations derived from the manual arterial blood samples (excluding the 2.5-min-after-injection sample) were used to individually calibrate each online (whole-blood) sampler curve. Next, this calibrated whole blood curve was transferred into a total plasma curve by multiplying it with a three exponential function that was fitted to the plasma-to-whole-blood ratios derived from all manual samples. Finally, the resulting total plasma curve was multiplied with a Hill function fitted to the time-course of the parent fractions 18 , resulting in a metabolite-corrected arterial plasma input function.
Tissue time-activity curves were fitted to irreversible and reversible one (1T1K: K 1 ; 1T2K: K 1 , k 2 which are in-and efflux rate constants, respectively), and two (2T3K: K 1 , k 2 , k 3 ; 2T4K: K 1 , k 2 , k 3 , k 4; these are all rate constants for transfer between tissue compartments) tissue compartment models using the metabolite corrected plasma curve as input function. In all these models, blood volume V B was included as a fit parameter (using the calibrated whole-blood curve as its input function). In addition, a dual-input model with parallel parent and metabolite plasma input functions (Fig. 1) was investigated. The Akaike Information Criterion (AIC) was used to select the best model. 19 Finally, the possibility of reducing scan duration was investigated by removing an increasing number of frames from the end of each scan. Resulting outcome parameters were compared with those obtained from the full scan using correlation analysis and Bland-Altman plots.
statistical analysis
Test-retest variability was calculated as the absolute difference between test and retest scan values divided by their mean. 12 P values for assessing differences in characteristics between test and retest scans were obtained using nonparametric Wilcoxon signed-rank tests. Data are presented as mean ± standard deviation (SD), unless otherwise stated.
resulTs
Twelve healthy subjects were included (6 men; mean age 32 years, age range 19 to 63 years). As a result of technical problems (occlusion arterial line, tracer production fail-
Dual input model C P and C m represent plasma concentrations of parent tracer and labeled metabolites, respectively, and C T the concentration in tissue, K 1 and k 2 represent influx and efflux rate constants for parent tracer, respectively, and K 1m and k 2m influx and efflux rate constants for labeled metabolites, respectively ure), test-retest data of 8 subjects (5 men; mean age 30 years, age range 19 to 43 years) were available for analysis. Seven underwent 2 identical PET scans on the same day, and in 1 subject the second scan was performed 1 month after the first.
blood analysis
Plasma-to-whole-blood ratios and average parent fractions in plasma derived from the manual blood samples are shown in Figure 2 . The plasma-to-whole-blood ratio decreased from 1.66 at the beginning of the scan to 1.23 at 60 minutes after tracer injection ( Fig. 2A) . Metabolism of [ 11 C]laniquidar was relatively fast with only 50 and 20% of parent tracer left at 10 and 60 minutes after tracer injection, respectively (Fig. 2B) . No non-polar metabolites were detected.
Kinetic analysis
Kinetic analysis (n=8) of [ 11 C]laniquidar was complicated by low cerebral uptake and fast plasma clearance. Typical images at different time points after tracer injection are shown in Figure 3 . Cerebral [ 11 C]laniquidar uptake slowly increased over time (Fig. 4) suggesting irreversible or at least very slow binding. According to AIC, the 1T1K model was preferred over all standard plasma input models for 15 of the 16 scans, primarily because k 2 was very close to zero and therefore additional kinetic parameters did not improve the quality of the fits. Although the 1T1K model provided the best fits to the 60-minutes time-activity curves, there were systematic differences between fits and measured data at early time points (Fig. 4A) . Taking into account that radiolabeled metabolites of [ 11 C]laniquidar, probably (Table 1 ). In contrast, fitted values for parent K 1 showed good precision (Table 1) and were close to those of the 1T1K model. Given the simplicity of the 1T1K model, it seemed likely that scan duration could be shortened to simplify the scanning procedure, possibly enabling more patients to be scanned from a single tracer production. Several scan durations were investigated indicating that a 5-minutes scan was sufficient for stable estimates of K 1 . Global brain K 1 values were approximately 10% lower when only the first 5 rather than the full 60 minutes of scan data were used. This difference of ~10% was also observed at a regional level, with the exception of small ROIs (medial temporal lobe and anterior cingulate, both < 15mL) where on average up to 17% differences were observed. Global brain K 1 values for test and retest were 0.019 ± 0.002 and 0.021 ± 0.005, respectively, for 60-minutes tissue data (1T1K model). Corresponding values for just the first 5 minutes of data were 0.017 ± 0.002 and 0.019 ± 0.005, respectively. Figure 5 shows the relationship between K 1 values derived from 5 and 60 minutes of tissue data.
Test-retest variability
There were no differences between baseline and retest scans with respect to injected dose (347 ± 59 and 366 ± 27 MBq, respectively; p = 0.48) and specific activity (46 ± 26 and 71 ± 47 GBq·µmol -1 , respectively; p = 0. ), influx and efflux rate constants for parent tracer, respectively; K 1m (mL·cm (dual-input model). This variability was similar at regional level when the 1T1K model was applied. However, regional fits using the dual-input model were unstable. dIsCussIon This is the first study, to our knowledge, in which kinetics and uptake of the third-generation P-glycoprotein inhibitor [ 11 C]laniquidar in the human brain were investigated.
Several tracer kinetic models were assessed, but given the fact that k 2 was close to zero, the best model was a single-tissue compartment model with a single parameter (K 1 ) for which 5 minutes of data collection was sufficient. This reduced scanning time was investigated, as it is very patient friendly and in principle several patients could be scanned using a single temporal resolution is needed. It should be noted, however, that K 1 itself has limitations as a measure of P-glycoprotein expression, as in general K 1 is flow-dependent and, even in the same subject, day-to-day variations in cerebral blood flow do exist. 21 In the case of [ 11 C]laniquidar, however, K 1 not necessarily is the product of cerebral blood flow and extraction fraction, as its main target is located on the capillary wall. Probably K 1 represents a combination of P-glycoprotein expression and affinity for P-glycoprotein and possibly perfusion. Studies using combined 15 O-water and [ 11 C]laniquidar scans will be needed to determine the role of perfusion. Theoretically, a single-tissue compartment model with k 2 = 0 would be consistent with an irreversible inhibitor of P-glycoprotein. To conclusively determine whether [ 11 C]laniquidar indeed acts as an inhibitor rather than as a substrate tracer in humans needs to be derived from future blocking studies. For the 1T1K model, K 1 values reduced by about 10% when only the first 5 minutes of tissue data were used for analysis, indicating that later time points still affected K 1 . One possible explanation could be an increasing effect of (uptake of ) radiolabeled metabolites with increasing scanning duration, Nevertheless, the correlation between K 1 values derived from 5-and 60-minutes data sets was good (Fig. 5) . The analysis using 5 minutes of tissue data was performed using the entire plasma curve (60 minutes). To shorten study duration in future studies, the acquisition time of plasma data should also be shortened. Unfortunately, the present study protocol was not optimised for 5-minutes acquisition of plasma data. Nevertheless, the 5-minutes tissue data were reanalysed using only information from the first 5 minutes of plasma data. Resulting K 1 values were, on average, essentially the same as those derived from the analysis using all plasma data, although there was somewhat more spread in individual values. This indicates that, after optimising, it should be feasible to shorten acquisition of plasma data to 5 minutes.
As would result from hydrolysis of the methyl ester. As this metabolite is likely to enter the brain and plasma levels of labeled metabolites were high, a dual-input model was evaluated. This model, accounting for uptake of both [ 11 C]laniquidar and its labeled metabolites, provided good fits with reversible kinetics. Unfortunately, fitted parameters, especially V T , suffered from high variability ( Table 1) . Although there are limitations in the use of K 1 (see discussion above) for assessing P-glycoprotein expression in the case of reversible inhibitors, the use of V T for reversible inhibitors also is not clear-cut. V T reflects the ratio of K 1 and k 2 , which traditionally reflect rate constants for transport into and out of the brain, respectively. For P-glycoprotein, being located at the capillary wall, V T would only reflect P-glycoprotein expression if K 1 and k 2 reflect P-glycoprotein on and off rates, respectively. If the tracer also enters brain tissue, both these parameters will represent a mixture of binding characteristics to P-glycoprotein in the capillary wall, and transport in and out of the brain, complicating interpretation of measured V T values.
It has been suggested that, at tracer doses, laniquidar may act as a P-glycoprotein substrate rather than as a P-glycoprotein inhibitor, because cerebral [
11 C]laniquidar uptake was significantly higher in the presence of 60 mg·kg -1 of laniquidar in wild-type mice. 22 Furthermore, significantly increased cerebral uptake of [ 11 C]laniquidar has been observed in rats pretreated with the P-glycoprotein inhibitor cyclosporine A. 10 Being a P-glycoprotein substrate would provide a plausible explanation for low cerebral uptake in the present study. Another explanation for low cerebral [ 11 C]laniquidar uptake could be that interaction between [ 11 C]laniquidar and P-glycoprotein takes place at the bloodbrain barrier, which only constitutes 0.1% of the total brain weight. 23, 24 In other words, the physical space for tracer accumulation is limited compared with that of a tracer that enters the brain. Recently it has been postulated that not only very low P-glycoprotein density in the brain but also high protein binding of highly lipophilic P-glycoprotein inhibitors such as laniquidar, which in turn results in locally reduced plasma concentrations of the tracer of approximately 0.05%, accounts for the low cerebral [ 11 C]laniquidar uptake. 25 Unfortunately, in the present study a significant difference in injected mass of laniquidar between test and retest scans was observed. Nevertheless, specific activity was 20 GBq·µmol -1 or higher, and therefore no pharmacological effects would be expected. In addition, test-retest variability for both dual-input and 1T1K models was approximately 19% and no significant differences in K 1 between test and retest [ 
